uttmedical

A groundbreaking Israeli innovation for the direct treatment of bladder cancer, with no side effects.

UTT Ltd. is developing a biodegradable sponge embedded with a chemotherapy drug, designed for easy insertion for the treatment of bladder cancer, with no side effects for the patient. At the end of the treatment, the sponge biodegrades and dissolves.
24 Days to go

0% of funding target

₪75,000

Minimum investment
To view the table of benefits in the current fundraising round, please click here
Investment type:
Equity
Company Stage:
Seed
Category:
Medical Devices

Highlights

Highlights


Pitch

Pitch

Team

Team

אלי בן הרוש
ד"ר אשר הולצר
יוש דולברג
בוריס גילברט
ד"ר איירין זיתון
Dr. Shira Chatumi, MD
סוזן אלפרט
פרופ' דוד מרגל
ליאור נשר

Financial data

Financial data

Updates

Updates

Currently there are no updates in this pitch

Amount benefit
Investment from an amount of ₪100,000 and up to an amount of ₪300,000 an addition of 3.00% of the the shares value
Investment from an amount of ₪300,001 and up to an amount of ₪700,000 an addition of 5.00% of the the shares value
Investment from an amount of ₪700,001 and up to an amount of ₪1,000,000 an addition of 7.00% of the the shares value
Investment from an amount of ₪1,000,001 and up to an amount of ₪3,000,000 an addition of 10.00% of the the shares value

Example A

  • Investment of ₪700,000
an addition of of the the shares value

Example B

  • Investment of ₪560,000
an addition of of the the shares value

Example C

  • Investment of ₪1,010,000
an addition of of the the shares value
An investor who makes an investment of ₪700,000 ill be entitled to additional shares at a rate of of the amount of shares that would have been issued to said investor had he not been entitled to any benefit
An investor who makes an investment of ₪560,000 ill be entitled to additional shares at a rate of of the amount of shares that would have been issued to said investor had he not been entitled to any benefit
An investor who makes an investment of ₪1,010,000 ill be entitled to additional shares at a rate of of the amount of shares that would have been issued to said investor had he not been entitled to any benefit
The financing rounds, made through the ExitValley platform, are in accordance with a model of statutory exemption from publishing a prospectus pursuant to sections 15A(A)(1) and 15A(A)(7) of the Israeli Securities Law - 1968.
Under this model, the disclosure of detailed information on the company and information about the investment in each round of financing are limited to not more than 35 investors, who are not qualified investors, and the round of financing is not in the format of an offering arrangement ("רכז הצעה"), as defined in the Securities Law.
Follow us